Regulatory Focus™ > News Articles > 2 > Recon: AstraZeneca Spins Out $250M Biotech Company

Recon: AstraZeneca Spins Out $250M Biotech Company

Posted 28 February 2018 | By Ana Mulero 

Recon: AstraZeneca Spins Out $250M Biotech Company

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing.
In Focus: US
  • AstraZeneca spins out new firm Viela Bio (The Pharma Letter) (Reuters) (Press)
  • Amid PBM Market Concerns, Express Scripts Sets High Retention Goal (Forbes) (Press)
  • Justice Department sides with states in nationwide opioid lawsuit against distributors, manufacturers (Stat News) (DOJ) (E&C Hearing)
  • Mallinckrodt subpoenaed, again, over sales of oxymorphone in growing opioid crisis (Fierce)
  • NORD to Collaborate with FDA on Pilot Patient Engagement Activity (Press) (Pink Sheet-$)
  • U.S. Prescription Drug Costs Are a Crime (Bloomberg)
  • Going Strong! Orphan Drug Approvals and Designations Skyrocketed in 2017, While Orphan Drug Designation Requests Dipped Slightly (FDA Law Blog)
  • On this Rare Disease Day, let’s all commit to helping recognize the life and work of biotech giant Henri A. Termeer (Endpoints)
  • FDA research to improve technique for studying multipotent stromal cell morphology (FDA)
  • NIAID Unveils Strategic Plan for Developing a Universal Influenza Vaccine (NAID)
In Focus: International
  • Bayer to win EU approval for $62.5 billion Monsanto deal (Reuters) (Fierce)
  • Billionaire-Backed Cancer Testing Firm Plans Hong Kong IPO (Bloomberg)
  • Novartis’ oncology research chief in China jumps to upstart EpimAb in Shanghai (Endpoints) (Fierce)
  • European Commission approves Hemlibra, first new hemophilia A treatment in 20 years (The Pharma Letter) (Press)
  • Nortech Systems is expanding its Mexico operations (Medical Design & Outsourcing)
  • WHO cancer agency “left out key findings” in benzene review (Reuters)
  • Roche out-licenses commercialization of Actemra and Avastin in India (The Pharma Letter)
  • Second wave of NHS England test beds launched (MHRA)
  • Nigeria battles its largest Lassa fever outbreak on record (WHO)
Pharmaceuticals & Biotechnology
  • Celgene stumbles again, as FDA declines to review multiple sclerosis drug critical to company future (Stat News) (Forbes) (Focus)
  • This Valeant Chart Looks Great (Just Don't Try to Measure It) (Bloomberg)
  • Novo Holdings ponies up $165M for superbug venture fund (Fierce)
  • BeiGene Announces Approval of REVLIMID for Newly Diagnosed Multiple Myeloma in China (Press)
  • Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint (Stat News)
  • Speedy EU review for Shire’s lanadelumab (The Pharma Letter)
  • Comment Request; Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings With the Office of Orphan Products (FDA)
  • Recap of Access! 2018 — Chip's Call to Action (Part 2) (AAM)
  • Judge's ruling sets Shkreli up for possible 10 years in prison, but he seeks leniency for his good deeds (Fierce)
  • Citizen Petition from Buchanan Ingersoll & Rooney PC (on behalf of Synergy Pharmaceuticals Inc.) (Petition)
  • Acorda Enters Into Cooperation Agreement with Scopia (Press)
  • Teva Announces Launch of Offering of Senior Notes (Press)
  • Fast Pace of Drug and Device Approvals in 2017 Signals Wider Sector Health for Biopharma but Medtech Companies Struggle, Says EP Vantage (Press)
  • Johnson & Johnson Human Performance Institute Invests in the Future of Wellbeing with New $18 Million Facility in Lake Nona Medical City (Press)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • What’s in the IV bag? Studies show safer option than saline (Stat News)
  • GW’s cannabidiol gets EU orphan status for TS (The Pharma Letter)
  • FDA solicitation for research and development to support regulatory science and innovation (FDA)
  • Armed with published animal data, gene-editing pioneer Intellia maps the road to an IND (Endpoints)
  • Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve (Press)
  • Promising HIV vaccines could stall without coordinated research (Nature)
  • Field evidence for manipulation of mosquito host selection by the human malaria parasite, Plasmodium falciparum (bioRxiv)
  • This scientist is testing a marijuana ingredient as a way to prevent relapse. It’s a daunting task (Stat News)
Medical Devices
  • AI and facial diagnosis company FDNA sets up genomics coalition (Fierce)
  • Medtronic and Lehigh Valley Health Network Sign Strategic Partnership Agreement Focused on Delivering Value-Based Healthcare Programs (Press)
  • InterSystems and ZOLL Medical Corporation Collaborate to Integrate Emergency Medical Services into Care Continuum (Press)
  • Patients would like their data, please. Will the medical device industry listen? (Stat News)
  • Brain Implant for Some Blind People Shows Benefits of FDA’s Breakthrough Device Program (FDA Voice)
  • Microsoft’s focus on transforming healthcare: Intelligent health through AI and the cloud (Microsoft)
  • TDK to acquire Chirp Microsystems, aiming for leadership in ultrasonic sensing solutions (Press)
  • Elligo Health Research and Saama Technologies Announce Strategic Partnership to Advance Clinical Research Data Management (Press)
US: Assorted & Government
  • E6(R2) Good Clinical Practice: Integrated Addendum to E6(R1); International Council for Harmonisation; Guidance for Industry (FDA)
  • Utilization Management Strategies to Address the Opioid Crisis (CVSHealth)
  • US economic growth revised down to 2.5 percent (The Hill)
  • FTC Recommends Steps to Improve Mobile Device Security Update Practices (FTC)
  • Under Trump, the pace of FDA regulations slowed to a trickle (Stat News)
  • New opioid bill would impose sweeping limits on some prescriptions, boost funding (Stat News)
  • There's a shortage of opioids where they're needed most - in hospitals (Philly.com)
  • A Modest Proposal Redux (Patent Law Weblog)
  • Meunerie Sawyerville, Inc.; Denial of Hearing; Final Debarment Order (FDA)
  • Prescription for secrecy (Journal Sentinel)
Upcoming Meetings & Events Europe
  • List of medicines under additional monitoring (EMA)
  • Recommendations on eligibility to PRIME scheme (EMA)
  • NAMSA Introduces French Website to Provide Resource for Accelerated Medical Device Development in Europe (Press)
Asia India
  • No discrimination: on health insurance in India (The Hindu)
  • Google Brings Health 'Symptom Search' Feature to India (News18)
  • US pharma concerns on IP rights and compulsory licensing in India (The Pharma Letter)
  • Why Indian pharma need to track Amazon's plans in health care (Business Today)
Australia
  • One in six Australian women suffer physical or sexual abuse from partner (The Guardian)
  • Paragon Care Ltd to acquire a surgical medical device company (Motley Fool Australia)
  • MedX Health Corp. Announces Regulatory Clearance for its SIAscopy Medical Devices in New Zealand (Press)
Canada
  • More than 200 Quebec doctors oppose proposed pay raise for themselves (Toronto Star)
General Health & Other Interesting Articles
  • A Big Divergence Is Coming in Health Care Among States (NY Times)
  • A Secretive Sect Opens A Debate On Female Genital Mutilation (NPR)
  • Microsoft and UPMC unveil virtual AI assistant that listens in and takes notes on doctor’s visits (GeekWire)
 Need to contact the editor of Regulatory Reconnaissance? Send us an email at news@raps.org.
 
A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.
 

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe